Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

Lizarosey Feb. 28 at 10:30 AM

$ABBV pharmaceutical portfolio strength visible

0 · Reply

Dr_Feel_Good Feb. 28 at 4:56 AM

Solid finish to end the week led by $DRD $NFLX $ABBV $AMBP and $RTX. Have A Good Weekend Fam 🌊🏄‍♂️🤙

0 · Reply

maikl_211 Feb. 28 at 2:31 AM

$BAC $ABBV $MU $GE $PG

1 · Reply

leshgo Feb. 28 at 1:52 AM

$VKTX Things are moving really fast right now. Kailera has deep ties to China. However, on Feb 23, $ABBV announced a $100 billion investment in the U.S., which includes building a manufacturing facility for obesity drugs by 2029. Given ABBV's close cooperation with the U.S., I think the chances of them considering a China-linked company like Kailera are extremely slim. With zero ties to China and the absolute best data in late-stage trials, $VKTX is undeniably the top-tier choice. This feels like way more than just simple speculation—the probability actually looks incredibly high. @biolover

2 · Reply

maikl_211 Feb. 27 at 9:51 PM

$PLTR $COST $NFLX $BAC $ABBV

0 · Reply

Stockman824 Feb. 27 at 9:42 PM

$ABBV $VKTX I’ll take Viking for 15 billion 50/50 partnership next week Alex

0 · Reply

Dr_Stoxx Feb. 27 at 9:17 PM

$ABBV got some love today

0 · Reply

biolover Feb. 27 at 8:39 PM

$VKTX $ABBV named obesity as their 4th pillar. They got spoiled by cheap GUBRA deal. But realized it is not an impressive asset. Abbv can easily allocate $20 B for right market ready obesity asset ( for institutions that value $VKTX for $4 B) but unknown how much VK CEO asking for ?

1 · Reply

biolover Feb. 27 at 6:53 PM

$ABBV $VKTX zero chance ABBV is not doing obesity BD this year. Either Viking or Kailera. Again for people willing to wait nothing will match waiting till 2027. Abbv choice based on how much they understand data. Managment clearly appreciates obesity market size and potential, opposite of Bourla that only changed his mind after Lilly q3 ( too late ).: and now sees it as big as it is.

0 · Reply

KetCopyPaste Feb. 27 at 5:56 PM

$VKTX $ABBV I’ve seen some chatter on this. To clarify. DD: Senior Notes Offering – 02/24/2026 AbbVie announced it launched a senior notes offering totaling ~$7.95B in multiple tranches with expected net proceeds of about $7.95B, according to the filing dated Feb. 24, 2026. The offering spans maturities from 2028 to 2066 and includes fixed and floating rate notes. The company plans to use the proceeds to repay outstanding amounts under its 364-day delayed draw term loan facility and for general corporate purposes, which may include repaying or repurchasing other debt. This is debt financing, not equity issuance, so it should not dilute shareholders. It bolsters liquidity and provides flexibility for refinancing and balance sheet management. Link: https://www.gurufocus.com/news/8659743/abbvie-abbv-announces-795-billion-senior-notes-offering

0 · Reply

Best Dividend Aristocrats For March 2026

ABT ADM ADP AFL ALB AMCR AOS

Feb 26, 2026, 7:30 AM EST - 2 days ago

Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie

MRK

Feb 24, 2026, 8:00 AM EST - 3 days ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 12:03 PM EST - 4 days ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

Feb 23, 2026, 11:00 AM EST - 4 days ago

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

Feb 20, 2026, 2:00 AM EST - 8 days ago

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Feb 19, 2026, 9:37 AM EST - 8 days ago

AbbVie Declares Quarterly Dividend

Feb 17, 2026, 1:11 AM EST - 11 days ago

AbbVie: Dominating Immunology While Building Oncology Upside

Feb 13, 2026, 12:57 PM EST - 14 days ago

AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript

Feb 12, 2026, 7:30 AM EST - 16 days ago

54 Stocks, 9 Megatrends: My Favorite Places To Be While Capital Is 'Forced'

AM APH AR ASML AVAV BTU CARR

Feb 11, 2026, 6:49 PM EST - 16 days ago

AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 5:13 PM EST - 16 days ago

Abbvie sues US health agency over Botox

Feb 11, 2026, 4:06 PM EST - 16 days ago

2 Urgent Sells And 2 No Brainer Dividend Buys

AEP AMGN BMY ESS HASI HD PFE

Feb 10, 2026, 9:45 AM EST - 17 days ago

Dividend Kings: No Ideal Buys In February's 57

ABM ADP CWT FRT FTS HRL HTO

Feb 5, 2026, 8:52 AM EST - 22 days ago

AbbVie: The Market Is Getting It Wrong

Feb 5, 2026, 4:25 AM EST - 23 days ago

AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot

Feb 4, 2026, 6:04 PM EST - 23 days ago

AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise

Feb 4, 2026, 5:45 PM EST - 23 days ago

AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake

Feb 4, 2026, 3:39 PM EST - 23 days ago

AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)

Feb 4, 2026, 1:20 PM EST - 23 days ago

AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript

Feb 4, 2026, 12:38 PM EST - 23 days ago

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

Feb 4, 2026, 8:34 AM EST - 23 days ago

AbbVie Revenue Rises on Immunology Growth

Feb 4, 2026, 8:18 AM EST - 23 days ago

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.

Feb 4, 2026, 7:51 AM EST - 23 days ago

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

Feb 4, 2026, 7:48 AM EST - 24 days ago

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Feb 3, 2026, 8:50 AM EST - 24 days ago

Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

Feb 3, 2026, 8:00 AM EST - 24 days ago

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

Jan 29, 2026, 10:30 PM EST - 4 weeks ago

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

ABVX CVLT FIX FTAI GKOS GMAB HLI

Jan 29, 2026, 10:10 AM EST - 4 weeks ago

10 Highest Rated Dividend Kings For Generations Of Income

ABM ABT ADM BDX BKH KMB KO

Jan 29, 2026, 8:00 AM EST - 4 weeks ago

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

Jan 28, 2026, 8:00 AM EST - 4 weeks ago

Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

Jan 27, 2026, 4:52 PM EST - 4 weeks ago

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

LLY PFE

Jan 27, 2026, 9:34 AM EST - 4 weeks ago

The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator

Jan 25, 2026, 10:11 PM EST - 4 weeks ago

Best Dividend Kings: January 2026

ABM ABT ADM ADP AWR BDX BKH

$AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)$

Jan 16, 2026, 1:43 PM EST - 6 weeks ago

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jan 16, 2026, 1:35 PM EST - 6 weeks ago

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

GMAB

Jan 14, 2026, 5:45 PM EST - 6 weeks ago

AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 2:01 PM EST - 6 weeks ago

AbbVie plans to build out its presence in obesity market

Jan 13, 2026, 7:22 AM EST - 6 weeks ago

AbbVie reaches 3-year deal with White House to lower drug prices

Jan 13, 2026, 5:24 AM EST - 6 weeks ago

AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.

Jan 12, 2026, 7:03 PM EST - 6 weeks ago

AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices

Jan 12, 2026, 6:57 PM EST - 6 weeks ago

Abbvie, US reach agreement to cut drug prices

Jan 12, 2026, 6:30 PM EST - 6 weeks ago

AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans

Jan 12, 2026, 7:39 AM EST - 6 weeks ago

AbbVie, RemeGen partner on experimental solid tumor treatment

Jan 12, 2026, 7:30 AM EST - 6 weeks ago

AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

Jan 12, 2026, 6:00 AM EST - 6 weeks ago

AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States

WST

Jan 12, 2026, 6:00 AM EST - 6 weeks ago

West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie

WST

Jan 12, 2026, 5:12 AM EST - 6 weeks ago

Dividend Income: Lanny's November 2025 Summary

AFL CAT COF CVS CZNC EMR ETN

Jan 10, 2026, 9:30 AM EST - 6 weeks ago

MoneyShow's Best Investment Ideas For 2026: Part 1

ABR ACHR ARE ARES ASTS

Jan 8, 2026, 12:07 PM EST - 7 weeks ago

AbbVie: The Dividend Does Not Lie

Lizarosey Feb. 28 at 10:30 AM

$ABBV pharmaceutical portfolio strength visible

0 · Reply

Dr_Feel_Good Feb. 28 at 4:56 AM

Solid finish to end the week led by $DRD $NFLX $ABBV $AMBP and $RTX. Have A Good Weekend Fam 🌊🏄‍♂️🤙

0 · Reply

maikl_211 Feb. 28 at 2:31 AM

$BAC $ABBV $MU $GE $PG

1 · Reply

leshgo Feb. 28 at 1:52 AM

2 · Reply

maikl_211 Feb. 27 at 9:51 PM

$PLTR $COST $NFLX $BAC $ABBV

0 · Reply

Stockman824 Feb. 27 at 9:42 PM

$ABBV $VKTX I’ll take Viking for 15 billion 50/50 partnership next week Alex

0 · Reply

Dr_Stoxx Feb. 27 at 9:17 PM

$ABBV got some love today

0 · Reply

biolover Feb. 27 at 8:39 PM

1 · Reply

biolover Feb. 27 at 6:53 PM

0 · Reply

KetCopyPaste Feb. 27 at 5:56 PM

0 · Reply

Luckyjs38 Feb. 27 at 5:50 PM

$ENVB @Enveric_Bio In my opinion EB-003 will be worth over 1 billion dollars after it proves to be safe & effective. Similar drug $ABBV just acquired Gilgamesh Pharmaceuticals. lead drug, bretisilocin—a next-gen psychedelic that’s basically a short-trip version of stuff like psilocybin. It’s a serotonin 5-HT2A agonist designed for major depressive disorder, with way less time spent “tripping” for 1.3 Billion. Now think if EB-003 doesn’t active hallucinations how much more marketable their drug would be. A market cap equivalent of 1 Billion would put this company trading at around $720 🌎❤️ Do your DD Cambridge ,MA based next generation biopharmaceutical company of the future 👀🇺🇸

0 · Reply

Luckyjs38 Feb. 27 at 4:48 PM

$ABBV $ENVB

0 · Reply

67X_ROI_Q1_2026 Feb. 27 at 3:56 PM

$SLS Best Available Treatment (BAT) Aza+VEN for Control ARM Patients, Recently Failed 3 Large Phase 3 Trials Conducted by $ABBV Meanwhile, we are seeing Miraculous ALL POOLED Survival Data in the SLS Phase 3. ALL POOLED = Control ARM on BAT/Aza+VEN and GPs Patients Combined. it is not complicated. Gps has proven effective at Preventing Relapse and Extending Survival in ALL Previous Trials. https://www.reddit.com/r/sellasLifescience/

1 · Reply

Luckyjs38 Feb. 27 at 3:22 PM

$ABBV Was a settlement reached? Between $ABBV & $ENVB ? 🧐

0 · Reply

67X_ROI_Q1_2026 Feb. 27 at 7:45 AM

$SLS $ABBV rNPV - What is Gps Worth?

0 · Reply

67X_ROI_Q1_2026 Feb. 27 at 5:44 AM

$SLS $ABBV Bottom Line: Given the Variable nature of events and the extended length of duration for patients remaining in trial, - there could easily be a rapid spate of successive events, at any time, and Institutional Funds, and all interested/invested parties must reconcile their positions with this Fact, we could see Final Topline Results any day now. https://www.reddit.com/r/sellaslifesciences/s/4tCZDr8dtw interesting last post from Gabri, CR2 Patients GETTING TRANSPLANT have a MOS LESS than < GPS P2 patients INELIGIBLE FOR TRANSPLANT. - says it all.

0 · Reply

kellysmith1 Feb. 26 at 11:37 PM

$ABBV $BMY $MRK $PMN $SNY look at NVO now..

0 · Reply

67X_ROI_Q1_2026 Feb. 26 at 11:06 PM

$SLS $ABBV - The Instant the Market Sees the Phase 3 Registrational Results, Gps is worth $40B + to Big Pharma. —- Every day we wait, the pressure will ratchet. The share price will keep climbing until it Launches. Shorts Know...

0 · Reply

67X_ROI_Q1_2026 Feb. 26 at 10:50 PM

$SLS $ABBV No Real Holders are letting any shares go with the Phase 3 Results Now Imminent - in the ANY DAY NOW Zone. And SMART Money is Buying Every Share idiots will Sell. - Gps is getting the FDA Green light to treat 100,000 AML Patients Currently in Remission. - CCo estimated $280K Rev per Patient and Dosing is Infinite / 5 years for Cr1 Patients. $28 B TAM - that is worth $40B to Big Pharma / $180 Per Share the Instant the Phase 3 Results are Announced. from Yesterday - and in the in between time there will be Multiple Valuable Catalysts increasing shareholder value.

0 · Reply

67X_ROI_Q1_2026 Feb. 26 at 7:48 PM

$SLS $ABBV $5 is going to be $6 $7 within Days. Lots of Restricted Funds will now be accumulating ahead of the GPS Phase 3 Trial Results. Gps is about to Get the FDA Green light to treat 100,000 AML Patients Currently in Remission - $25B TAM. Gps will be worth $40B the Instant the Phase 3 Results are announced - and we are in the ANY DAY NOW Zone.

0 · Reply

67X_ROI_Q1_2026 Feb. 26 at 7:38 PM

$SLS $ABBV - in light of the Major FDA Policy Shift Announcement -- thought i'd re-up this for the Inch Thick, Mile wide Penny Flips -- you may like to reconsider for once in your short miserable life. The FDA Commissioner just explained how and why the GPS Phase 2 Trial for AML CR1 patients Conducted at MSKCC ensure GPS will be approved - at least Conditionally for CR1 patients as well As CR2/3 --- Adds 5x to SLS VALUE - the Share Price will be Jumping. +5 Brings in Pension Money - Margin Account Access

0 · Reply

67X_ROI_Q1_2026 Feb. 26 at 7:14 PM

$SLS $ABBV in light of the Major FDA Policy Shift Announcement -- thought i'd re-up this for the Inch Thick, Mile wide Penny Flips -- you may like to reconsider for once in your short miserable life. The FDA Commissioner just explained how and why the GPS Phase 2 Trial for AML CR1 patients Conducted at MSKCC ensure GPS will be approved - at least Conditionally for CR1 patients as well As CR2/3 --- Adds 5x to SLS VALUE - the Share Price will be Jumping.

0 · Reply

Market Cap	397.29B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	22.69
Forward PE	15.54
Profit Margin	6.91%
Debt to Equity Ratio	-26.45

Volume	8,018,000
Avg Vol	6,806,948
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	78%
Beta	0.35
Analysts	Strong Sell
Price Target	$248.86